|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
It was demonstrated that brucine inhibited vasculogenic mimicry which might be through the downregulation of erythropoietin-producing hepatocellular carcinoma-A2 and matrix metalloproteinase-2 and metalloproteinase-9.
|
30723742 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, we found that Bclaf1 promotes HIF1A transcription via its bZIP domain, leading subsequently to increased transcription of the HIF-1α downstream targets VEGFA, TGFB, and EPO that in turn promote HCC-associated angiogenesis and thus survival and thriving of HCC cells.
|
30367150 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Unfortunately, the role of EPO/EPOR in hepatocellular carcinoma (HCC) progressing is still uncertain.
|
29238266 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study aimed to investigate the expression of hypoxia inducible factor-2 subunit α (HIF-2α), vascular endothelial growth factor A (VEGFA), erythropoietin-producing hepatocellular A2 (EphA2) and angiogenesis in residual hepatocellular carcinoma (HCC), following treatment with high-intensity focused ultrasound (HIFU) ablation, in order to investigate the association between protein expression and tumor recurrence and growth.
|
28587437 |
2017 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of erythropoietin-producing human hepatoma (EPHB4) leads to enhanced cell migration, growth and adhesion in tumor cells.
|
28739744 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
EphrinB2 (erythropoietin-producing hepatoma interactor B2), a pivotal bidirectional signaling molecule ubiquitously expressed in mammals, is crucial in angiogenesis during development and disease progression.
|
28743805 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The mRNA levels of four candidate genes, cytokeratin 7 (<i>CK7</i>), E74-like factor 3 (<i>ELF3</i>), epidermal growth factor receptor (<i>EGFR</i>), and erythropoietin-producing hepatocellular carcinoma receptor B4 (<i>EphB4</i>) that were significantly elevated in tumor tissues and peripheral blood mononuclear cells (PBMCs) were determined.
|
27827952 |
2016 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Immunotherapy with genetically modified T cells expressing chimeric antigen receptors (CARs) targeting interleukin (IL) 13Rα2, human epidermal growth factor receptor 2, epidermal growth factor variant III or erythropoietin-producing hepatocellular carcinoma A2 has shown promise for the treatment of glioma in preclinical models.
|
24841514 |
2014 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of CSR enhanced the induction of erythropoietin and hypoxia response element (HRE) activity under hypoxia in human hepatocarcinoma cell lines (Hep3B), while knockdown of CSR suppressed them.
|
24491563 |
2014 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In vitro transfection assay showed that pEpo-AFPL-Luc transfected hepatoma cell increased gene expression under hypoxic condition.
|
23830978 |
2013 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, NB cells had maximal production of EPO with lower partial pressure of O(2) values than the well-characterized hepatoma cell line HepG2.
|
12239177 |
2002 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We used cDNA microarray technology to extend our studies pertaining to these molecular details in human hepatocellular carcinoma (Hep3B) cells that produce erythropoietin (Epo) in response to hypoxia.
|
11408933 |
2001 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
SCH-58261, a selective adenosine A(2A) receptor antagonist, significantly inhibited the increase in medium levels of Epo in Hep3B cell cultures exposed to hypoxia (1% O(2)).
|
11592940 |
2001 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment of human hepatoma cells (HepG2) with NO-donors for 24 h inhibited hypoxia-induced erythropoietin (EPO) gene activation.
|
11025195 |
2000 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Therefore, the effects of cadmium chloride (Cd) and CDDP in the Hep3B human hepatoma cell line, which up-regulates EPO expression in response to hypoxia and cobalt (Co), were investigated.
|
11090055 |
2000 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In order to investigate the role of NO in Epo production in Hep3B cells under normoxic (20% O2) conditions, we have studied the effects of interferon-gamma (IFN-gamma) on Epo production.
|
9126339 |
1997 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, reporter gene expression using chloramphenicol acetyltransferase assay demonstrated that the TR2 orphan receptor may suppress the expression of the chloramphenicol acetyltransferase activities via the TR2RE-EPO in the hypoxic/normoxic human hepatoma HepG2 cells.
|
8626614 |
1996 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The hepatoma cell line Hep 3B produces low basal levels of Epo mRNA which increase markedly with hypoxia.
|
8387202 |
1993 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This is the first demonstration of mutant EPO mRNA expression and bioactive mutant EPO protein in hepatocellular carcinoma tissue.
|
8396923 |
1993 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recent data suggest that the half-time of Epo messenger RNA (mRNA) is increased by hypoxia in Hep 3B cells, a human hepatoma line.
|
1653242 |
1991 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The human hepatoma cell line Hep3B regulates its production of Epo in a physiologic manner.
|
2849206 |
1988 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Only the human hepatoma cell lines, Hep3B and HepG2, made significant amounts of Epo as measured both by radioimmunoassay and in vitro bioassay (as much as 330 milliunits per 10(6) cells in 24 hr).
|
2825172 |
1987 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|